Total medical devices industry venture financing deals in February 2019 worth $432.16m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 55.8% over the previous month and a drop of 42.4% when compared with the last 12-month average, which stood at $750.46m.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $300.21m. At the country level, the US topped the list in terms of deal value at $300.21m.
In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of venture financing deals activity in February 2019 was the US with 31 deals, followed by China with seven and Israel with three.
In 2019, as of the end of February 2019, medical devices venture financing deals worth $1.41bn were announced globally, marking a decrease of 12.8% year on year.
Medical devices industry venture financing deals in February 2019: Top deals
The top five medical devices industry venture financing deals accounted for 70.5% of the overall value during February 2019.
The combined value of the top five medical devices industry venture financing deals stood at $304.8m, against the overall value of $432.16m recorded for the month. The top announced medical devices industry venture financing deal tracked by GlobalData in February 2019 was Kaiser Permanente Ventures, Norwest Venture Partners XII, Orbimed Advisors, Sands Capital Ventures, Sequoia Capital Operations and UPMC Enterprises’ $100m venture financing of Health Catalyst.
In second place was the $79m venture financing of Nuvaira by Advanced Technology Ventures, Endeavour Vision, LSV Capital Management, Morgenthaler Ventures, Qiming Venture Partners USA, Richard King Mellon Foundation, Split Rock Partners, USVP ManagementLlc, Versant Venture Management, Vertex Venture Holdings and Windham Venture Partners and in third place was Claremont Creek Ventures, Foresite Capital Management, GV Management Co, Innovatus Capital Partners, WuXi NextCODE Genomics and TPG Biotech’s $68m venture financing of DNAnexus.
The $30m venture financing of CathWorks by Deerfield ManagementLP and Go Capital, Jack Nicklaus II, Longliv Ventures, New Alliance Capital, OurCrowd and Steven Esrick’s venture financing of Sight Diagnostics for $27.8m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.